A physician-reviewed explainer separates erection firmness from permanent growth and places recurring erection changes in a wider health context.
On October 14, 2026, Ubie published a Doctor’s Note about whether BlueChew’s sildenafil- or tadalafil-containing tablets increase penis size. Its central clarification is straightforward: these medicines may support a firmer and fuller erection, but they do not permanently enlarge the penis.
The page says it was medically reviewed on October 13, 2026, by internal-medicine physician Yoshinori Abe, MD. It addresses a question where the meaning of “larger” matters. Greater fullness during an erection is different from a lasting change in anatomy.
That distinction also opens a more useful health conversation. Ubie points readers with persistent or changing erection difficulties toward clinical assessment, rather than assuming that medication alone answers the question. The update is about understanding what a medicine changes and keeping that separate from why an erection change happened.
Ubie’s publication is a physician-reviewed educational explainer rather than a report of a new clinical trial. There is no newly enrolled study population or follow-up period to describe. Its scope is the effect of sildenafil and tadalafil on erections, with particular attention to claims about size.
The page addresses a question about BlueChew, which it describes as offering chewable tablets containing sildenafil or tadalafil. The relevant health distinction concerns those medicines’ effects. The explainer is not a comparative study showing that one commercial service produces better outcomes than another.
Two clinical resources provide a broader frame for interpreting the update. The European Association of Urology’s erectile-dysfunction guidance covers clinical assessment and relevant health risks. A patient leaflet from Kent Community Health NHS Foundation Trust, titled “Erectile dysfunction and diabetes,” describes several possible contributors and advises discussing erection difficulties with a doctor.
These sources serve different purposes. The explainer answers a narrow question about medication effects. The guideline and leaflet place erection changes within a wider assessment of health.
According to Ubie, sildenafil and tadalafil improve blood flow to erectile tissue and may help an erection become firmer and fuller. They do not change penile anatomy or produce permanent enlargement.
The important distinction is between the state of an erection and the underlying structure. A fuller-looking erection during treatment reflects an effect on firmness and blood flow. It is not evidence that the medicine has caused lasting growth.
That matters when interpreting everyday words such as “bigger” or “fuller.” Someone using those words may be describing a change in erection quality rather than a change in size that remains outside the medicine’s effect. Keeping the outcome clearly named makes the claim easier to judge.
Ubie also says tadalafil may remain active for up to 36 hours. That is an effect window, not the duration of a continuous erection. The statement describes how long the medicine may remain active rather than how long an erection lasts.
These are separate questions: what changes during an erection and how long a medicine’s effects may be available. Neither the appearance of greater fullness nor the length of that window should be presented as permanent enlargement.
The Ubie page includes a numerical claim about improvement in erection hardness. It does not supply the underlying study details or a directly linked citation for that figure. Without those details, the claim should not be treated as a general success rate or a promise about an individual’s response.
The clinical context also needs careful interpretation. The European Association of Urology describes an association between erectile dysfunction and cardiovascular risk. That association is not proof that a particular person has cardiovascular disease.
Likewise, including hormonal assessment in a guideline does not establish that low testosterone explains any individual’s erection changes. The NHS leaflet identifies several possible contributors rather than a single cause that applies to everyone. Its focus on people with diabetes is also relevant when considering how broadly to apply its discussion.
The useful boundary is between recognising a possible contributor and identifying the explanation for one person. The sources support taking recurring changes seriously enough to discuss them. They do not support diagnosing a cardiovascular condition, hormone disorder or psychological problem from an erection change alone.
The new explainer’s emphasis on assessment fits the broader clinical guidance. It does not replace that guidance with a medication-centred explanation.
The European Association of Urology notes that erectile dysfunction is associated with increased cardiovascular-disease risk and should be considered a possible precursor of cardiovascular disease. This gives recurring erection changes relevance beyond sexual performance. In practical terms, the question belongs within a health discussion rather than being treated only as a question about firmness.
The same guidance includes early-morning total testosterone as part of hormonal testing. That places hormones within a clinical assessment. It is not a reason to assume that a hormone explanation must fit before the rest of someone’s history has been considered.
The Kent Community Health NHS Foundation Trust leaflet adds detail about other possible contributors. It lists some blood-pressure and depression medicines alongside low testosterone. It also includes stress and anxiety, depression and relationship difficulties.
Taken together, these sources resist a simple split between a “physical” problem and a “psychological” one. Their lists provide areas to consider during assessment, not competing labels that readers must choose for themselves. A medication question and a relationship question can both belong in the conversation without either being accepted as the answer in advance.
This is where the Ubie update is most useful. Its narrow correction about size sits within a broader message: an effect on erection firmness is not a complete explanation of sexual health. Learning what a medicine does is one task. Understanding a recurring change is another.
For readers, the immediate practical value is a more precise way to describe the concern. A question about permanent enlargement needs a different answer from a question about erections becoming less firm. Combining them can leave the actual concern unclear.
The NHS leaflet advises discussing erectile dysfunction with a doctor. For persistent or changing difficulties, that discussion offers a place to review possible contributors without deciding beforehand that medication or hormones must be the explanation.
A conversation can centre on questions such as:
These are discussion topics, not a self-diagnosis checklist. They help keep the original observation separate from assumptions about its cause. A concern can be described clearly even when the explanation is not yet known.
For readers preparing to talk about a change, an overview of what happens during a sexual health assessment provides related context. A guide to noticing and recording changes in sexual function offers another way to organise that conversation.
Questions about firmness can also be kept distinct from questions about interest or arousal. The guide to desire and different aspects of sexual response provides vocabulary for making those distinctions. The aim is clearer communication rather than finding a label for every change.
Medication review belongs with a qualified clinician. The leaflet’s list includes medicines that may contribute to erection difficulties, but that is not a reason to stop or change a prescription independently. Discussing the concern allows medication questions to stay connected to the health reasons those medicines were prescribed.
The opening question was whether these tablets make someone “larger.” The more useful perspective is to name the change accurately: Ubie describes improved firmness and fullness, not permanent growth. Once that distinction is clear, the conversation can move from an ambiguous size claim toward the person’s actual concern and its possible context.
Mistaking improved firmness for a complete explanation of sexual change leaves other questions unanswered, so Sexential places medication topics within a broader account of sexual wellbeing. Its coverage helps readers aged 35 to 65 separate hormonal and physical possibilities from psychological and relationship influences, making uncertainty easier to discuss without assigning a diagnosis or selecting treatment for an individual.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
